Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIG BUY'S :)
iBio for Production of Antibodies Targeting Ebola
iBio for Production of Antibodies Targeting Ebola
IBIO NEWS: Grants Caliber License for Production of Antibodies Targeting Ebola
NEWARK, DE, Nov 10, 2014 (Marketwired via COMTEX) -- iBio, Inc. (NYSE MKT: IBIO) and Caliber Biotherapeutics LLC executed an agreement, effective today, for an emergency use license to the iBioLaunch(TM) platform for production by Caliber of antibodies that target the Ebola virus.
As previously announced on January 15 and October 16, 2014, iBio and Caliber have had an ongoing collaborative relationship reflected by a License and Collaboration Agreement dated February 14, 2013. Since early September, both iBio and Caliber have been examining how they could use their technologies and facilities to assist governments to address the Ebola epidemic.
The license announced today expands Caliber's freedom to operate under iBio's issued U.S. patents and related intellectual property to enable Caliber to assist the U.S. government by manufacturing certain experimental drugs that address the current Ebola virus outbreak, to the extent such assistance is requested. Caliber operates the largest capacity cGMP manufacturing facility in the world capable to use iBio's technology for the production of monoclonal antibodies, other biotherapeutics, and vaccines.
On October 16, the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. government issued a Task Order Request to three pre-existing BARDA contractors, public-private consortia referred to as Centers for Innovation in Advanced Development and Manufacturing, for the procurement of a specified experimental Ebola therapeutic known as ZMapp(TM) made in Nicotiana plants. The submission deadline is November 10. None of the three consortia appears to have a plant-made pharmaceutical (PMP) technology or facility to produce significant quantities of the ZMapp experimental product in plants, so it is expected that the consortia interested to be involved will contract with PMP-capable parties in order to satisfy BARDA's requirements.
In addition to the Ebola-related activities, iBio and Caliber also are collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins that can benefit from the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods such as those which use Chinese hamster ovary (CHO) cells. According to peer-reviewed, published scientific data, recombinant antibodies produced in plants can provide significant efficacy advantages over similar antibodies produced in CHO cells. The companies are evaluating both proprietary and biosimilar products for a variety of markets.
IBIO NEWS: Grants Caliber License for Production of Antibodies Targeting Ebola
NEWARK, DE, Nov 10, 2014 (Marketwired via COMTEX) -- iBio, Inc. (NYSE MKT: IBIO) and Caliber Biotherapeutics LLC executed an agreement, effective today, for an emergency use license to the iBioLaunch(TM) platform for production by Caliber of antibodies that target the Ebola virus.
As previously announced on January 15 and October 16, 2014, iBio and Caliber have had an ongoing collaborative relationship reflected by a License and Collaboration Agreement dated February 14, 2013. Since early September, both iBio and Caliber have been examining how they could use their technologies and facilities to assist governments to address the Ebola epidemic.
The license announced today expands Caliber's freedom to operate under iBio's issued U.S. patents and related intellectual property to enable Caliber to assist the U.S. government by manufacturing certain experimental drugs that address the current Ebola virus outbreak, to the extent such assistance is requested. Caliber operates the largest capacity cGMP manufacturing facility in the world capable to use iBio's technology for the production of monoclonal antibodies, other biotherapeutics, and vaccines.
On October 16, the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. government issued a Task Order Request to three pre-existing BARDA contractors, public-private consortia referred to as Centers for Innovation in Advanced Development and Manufacturing, for the procurement of a specified experimental Ebola therapeutic known as ZMapp(TM) made in Nicotiana plants. The submission deadline is November 10. None of the three consortia appears to have a plant-made pharmaceutical (PMP) technology or facility to produce significant quantities of the ZMapp experimental product in plants, so it is expected that the consortia interested to be involved will contract with PMP-capable parties in order to satisfy BARDA's requirements.
In addition to the Ebola-related activities, iBio and Caliber also are collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins that can benefit from the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods such as those which use Chinese hamster ovary (CHO) cells. According to peer-reviewed, published scientific data, recombinant antibodies produced in plants can provide significant efficacy advantages over similar antibodies produced in CHO cells. The companies are evaluating both proprietary and biosimilar products for a variety of markets.
IBIO NEWS: Grants Caliber License for Production of Antibodies Targeting Ebola
NEWARK, DE, Nov 10, 2014 (Marketwired via COMTEX) -- iBio, Inc. (NYSE MKT: IBIO) and Caliber Biotherapeutics LLC executed an agreement, effective today, for an emergency use license to the iBioLaunch(TM) platform for production by Caliber of antibodies that target the Ebola virus.
As previously announced on January 15 and October 16, 2014, iBio and Caliber have had an ongoing collaborative relationship reflected by a License and Collaboration Agreement dated February 14, 2013. Since early September, both iBio and Caliber have been examining how they could use their technologies and facilities to assist governments to address the Ebola epidemic.
The license announced today expands Caliber's freedom to operate under iBio's issued U.S. patents and related intellectual property to enable Caliber to assist the U.S. government by manufacturing certain experimental drugs that address the current Ebola virus outbreak, to the extent such assistance is requested. Caliber operates the largest capacity cGMP manufacturing facility in the world capable to use iBio's technology for the production of monoclonal antibodies, other biotherapeutics, and vaccines.
On October 16, the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. government issued a Task Order Request to three pre-existing BARDA contractors, public-private consortia referred to as Centers for Innovation in Advanced Development and Manufacturing, for the procurement of a specified experimental Ebola therapeutic known as ZMapp(TM) made in Nicotiana plants. The submission deadline is November 10. None of the three consortia appears to have a plant-made pharmaceutical (PMP) technology or facility to produce significant quantities of the ZMapp experimental product in plants, so it is expected that the consortia interested to be involved will contract with PMP-capable parties in order to satisfy BARDA's requirements.
In addition to the Ebola-related activities, iBio and Caliber also are collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins that can benefit from the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods such as those which use Chinese hamster ovary (CHO) cells. According to peer-reviewed, published scientific data, recombinant antibodies produced in plants can provide significant efficacy advantages over similar antibodies produced in CHO cells. The companies are evaluating both proprietary and biosimilar products for a variety of markets.
Nice buy @the end. AH going higher imo
357 people wow, thats bad news.
Every day the same BS going to $2 going to $2,50 going to $5 STOP IT!!
Keep it real, Pre-Market Volume: 6,190 is noth huge.
Mod sticky post #10484
Good job.
nonsense, It is ibio related. and it's not up to you to judge whether it is fictional.
Link.
Rubbish!
200K BUY, GOING MUCH HIGER STRONGBUY!!
IBIO RUNNING 1,28
IBIO RUNNING 1,28
IBIO BIG BUYS 1,18
IBIO BIG BUYS 1,18
IBIO BREAKOUT
IBIO BREAKOUT
HEME VOLUME COMING IN
HEME VOLUME COMING IN
HEME 0.0007 250% Bruce Jay Howe, the new President of Health Med Services, said, "We know there is a lot of work to do in order to bring Health Med Services Ltd., back to the status of a full reporting company. However, with the guidance of our attorneys, accountants, and others, we look forward to the challenge, and to move forward with all the required and necessary filings as soon as we can. The 1World Direct JV the company is acquiring has a lot to offer Health Med Services in the way of new business, ideas, and technologies required to meet the growing and challenging needs for the worldwide health and medical services industry."
http://www.otcmarkets.com/news/otc-market-headline?id=16452450
HUNTINGTON BEACH, CA, Sep 17, 2014 (Marketwired via COMTEX) -- W Technologies, Inc. (PINKSHEETS: WTCG) announced today that it has agreed in principle to sell its Joint Venture with 1World Direct Hong Kong to Health Med Services, Ltd., (PINKSHEETS: HEME) for ten million shares of common stock of Health Med Services, Ltd.
Gary Koelsch, President of W Technologies, stated, "1World Direct of Hong Kong has several pending acquisitions, and joint ventures with other companies in the health and medical services business, and is expanding its network worldwide. In the best interest of W Technologies and its shareholders, we have decided to accept the offer from Health Med Services, Ltd. and sell our interest in the Joint Venture to them. The Health Med Services stock which will be issued to W Technologies, will be held by our corporate counsel until such time the transaction is closed and all the required reporting and filings have been completed. W Technologies will then distribute the Heath Med Services stock to its shareholders of record as an in-kind stock dividend. The closing date and shareholder of record date will be announced at a later time."
Bruce Jay Howe, the new President of Health Med Services, said, "We know there is a lot of work to do in order to bring Health Med Services Ltd., back to the status of a full reporting company. However, with the guidance of our attorneys, accountants, and others, we look forward to the challenge, and to move forward with all the required and necessary filings as soon as we can. The 1World Direct JV the company is acquiring has a lot to offer Health Med Services in the way of new business, ideas, and technologies required to meet the growing and challenging needs for the worldwide health and medical services industry."
HEME 0.0007 250% Bruce Jay Howe, the new President of Health Med Services, said, "We know there is a lot of work to do in order to bring Health Med Services Ltd., back to the status of a full reporting company. However, with the guidance of our attorneys, accountants, and others, we look forward to the challenge, and to move forward with all the required and necessary filings as soon as we can. The 1World Direct JV the company is acquiring has a lot to offer Health Med Services in the way of new business, ideas, and technologies required to meet the growing and challenging needs for the worldwide health and medical services industry."
http://www.otcmarkets.com/news/otc-market-headline?id=16452450
HUNTINGTON BEACH, CA, Sep 17, 2014 (Marketwired via COMTEX) -- W Technologies, Inc. (PINKSHEETS: WTCG) announced today that it has agreed in principle to sell its Joint Venture with 1World Direct Hong Kong to Health Med Services, Ltd., (PINKSHEETS: HEME) for ten million shares of common stock of Health Med Services, Ltd.
Gary Koelsch, President of W Technologies, stated, "1World Direct of Hong Kong has several pending acquisitions, and joint ventures with other companies in the health and medical services business, and is expanding its network worldwide. In the best interest of W Technologies and its shareholders, we have decided to accept the offer from Health Med Services, Ltd. and sell our interest in the Joint Venture to them. The Health Med Services stock which will be issued to W Technologies, will be held by our corporate counsel until such time the transaction is closed and all the required reporting and filings have been completed. W Technologies will then distribute the Heath Med Services stock to its shareholders of record as an in-kind stock dividend. The closing date and shareholder of record date will be announced at a later time."
Bruce Jay Howe, the new President of Health Med Services, said, "We know there is a lot of work to do in order to bring Health Med Services Ltd., back to the status of a full reporting company. However, with the guidance of our attorneys, accountants, and others, we look forward to the challenge, and to move forward with all the required and necessary filings as soon as we can. The 1World Direct JV the company is acquiring has a lot to offer Health Med Services in the way of new business, ideas, and technologies required to meet the growing and challenging needs for the worldwide health and medical services industry."
HEME 0.0005 X 0.0007 250%
HEME 0.0005 X 0.0007 250%
HEME 0.0004 X 0.0005 150%
HEME 0.0004 X 0.0005 150%
IBIO BREAKOUT
IBIO BREAKOUT
iBio Inc stock is poised to explode once again; however, it remains to be seen if the stock price gains will be sustained
http://www.bidnessetc.com/28329-ibio-stock-rides-the-rollercoaster-once-again/?utm_content=buffer1e4eb&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
News coming imo
Nurse Kaci Hickox breaks Ebola quarantine, leaves Maine home on bicycleā€¯
Hype?? you called ebola a hype. It's far from over...try again. the number of ebola patients doubled every 3 weeks